Verve Therapeutics Inc.

In News

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - TMX Newsfile

TMX Newsfile - Jun 02, 2026

Early data for heart drug affirm Lilly’s billion-dollar bet on Verve - BioPharma Dive

BioPharma Dive - May 26, 2026

Lilly Plans Phase II For VERVE-102 Gene-Editing Therapy After Early LDL-C Data - Citeline News & Insights

Citeline News & Insights - May 26, 2026

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - PR Newswire

PR Newswire - Jun 17, 2025

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk | Eli Lilly and Company - investor.lilly.com

investor.lilly.com - Jul 25, 2025

Verve Therapeutics, Inc. (VERV): A Bull Case Theory - Yahoo Finance

Yahoo Finance - Jul 10, 2025

Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments - CRISPR Medicine News

CRISPR Medicine News - Jun 17, 2025

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion - WSJ

WSJ - Jun 17, 2025

Lilly Acquires Verve Therapeutics - Contract Pharma

Contract Pharma - Jul 28, 2025

Lilly to Acquire Verve Therapeutics for Up to $1.3B - Genetic Engineering and Biotechnology News

Genetic Engineering and Biotechnology News - Jun 17, 2025

Lilly to Acquire Verve Therapeutics in $1.3B Deal Targeting One-Time Gene-Editing Treatments for Cardiovascular Disease - BioPharm International

BioPharm International - Jun 17, 2025

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B - Investopedia

Investopedia - Jun 17, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment